YIH
TYRA icon

Y-Intercept (HK)’s Tyra Biosciences TYRA Stock Holding History

Y-Intercept (HK)’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,942
Closed -$1.21M – 2072
2025
Q4 		$1.21M Buy
+45,942
New +$844K 0.03% 893

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Y-Intercept (HK)'s TYRA Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Tyra Biosciences (TYRA) in Q1 2026, closing a stake of 45,942 shares — an estimated $1.21M sold.

Y-Intercept (HK) first reported a position in TYRA in Q4 2025 and held it in 1 quarter. The position peaked at $1.21M in Q4 2025. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Y-Intercept (HK) reported no remaining Tyra Biosciences position as of Q1 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 45,942 Tyra Biosciences shares in Q1 2026, an estimated $1.21M.
  • Y-Intercept (HK) first reported a position in Tyra Biosciences in Q4 2025 and held it in 1 quarter.
  • Y-Intercept (HK)'s Tyra Biosciences position peaked at $1.21M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.